CZ20012029A3 - Přípravek se zlepąeným terapeutickým aplikačním rozsahem obsahující inhibitory nukleotidové syntézy - Google Patents

Přípravek se zlepąeným terapeutickým aplikačním rozsahem obsahující inhibitory nukleotidové syntézy

Info

Publication number
CZ20012029A3
CZ20012029A3 CZ20012029A CZ20012029A CZ20012029A3 CZ 20012029 A3 CZ20012029 A3 CZ 20012029A3 CZ 20012029 A CZ20012029 A CZ 20012029A CZ 20012029 A CZ20012029 A CZ 20012029A CZ 20012029 A3 CZ20012029 A3 CZ 20012029A3
Authority
CZ
Czechia
Prior art keywords
application range
therapeutic application
enhanced therapeutic
nucleotide synthesis
exhibiting enhanced
Prior art date
Application number
CZ20012029A
Other languages
English (en)
Inventor
Jürgen LINDNER
Burkhard Haase
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of CZ20012029A3 publication Critical patent/CZ20012029A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20012029A 1998-12-10 1999-12-01 Přípravek se zlepąeným terapeutickým aplikačním rozsahem obsahující inhibitory nukleotidové syntézy CZ20012029A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19857009A DE19857009A1 (de) 1998-12-10 1998-12-10 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren

Publications (1)

Publication Number Publication Date
CZ20012029A3 true CZ20012029A3 (cs) 2002-02-13

Family

ID=7890633

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012029A CZ20012029A3 (cs) 1998-12-10 1999-12-01 Přípravek se zlepąeným terapeutickým aplikačním rozsahem obsahující inhibitory nukleotidové syntézy

Country Status (30)

Country Link
EP (1) EP1137438B1 (cs)
JP (1) JP2002531525A (cs)
KR (1) KR20010080729A (cs)
CN (1) CN1189214C (cs)
AR (1) AR021577A1 (cs)
AT (1) ATE218370T1 (cs)
AU (1) AU766810B2 (cs)
BG (1) BG105548A (cs)
BR (1) BR9916006A (cs)
CA (1) CA2354266A1 (cs)
CZ (1) CZ20012029A3 (cs)
DE (2) DE19857009A1 (cs)
DK (1) DK1137438T3 (cs)
EA (1) EA005136B1 (cs)
EE (1) EE200100305A (cs)
ES (1) ES2178496T3 (cs)
HK (1) HK1041598B (cs)
HR (1) HRP20010429A2 (cs)
HU (1) HUP0104624A3 (cs)
IL (1) IL143586A0 (cs)
MX (1) MXPA01005861A (cs)
NO (1) NO20012719D0 (cs)
NZ (1) NZ511882A (cs)
PL (1) PL349336A1 (cs)
PT (1) PT1137438E (cs)
SI (1) SI1137438T1 (cs)
SK (1) SK284842B6 (cs)
WO (1) WO2000033876A1 (cs)
YU (1) YU39901A (cs)
ZA (1) ZA200104815B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
WO2002072527A2 (de) * 2001-03-13 2002-09-19 Protagen Aktiengesellschaft 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
CA2498045A1 (en) 2002-09-06 2004-03-25 Schebo Biotech Ag Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
WO2005060980A1 (ja) * 2003-12-24 2005-07-07 Masaakira Shonago 疾患治療用医薬及び糖尿病治療用医薬
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
DE59203828D1 (de) * 1991-10-23 1995-11-02 Hoechst Ag N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft.
IT1254519B (it) * 1992-03-16 1995-09-25 Chiesi Farma Spa Associazioni di composti ad attivita' antivirale
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
WO1998013047A1 (en) * 1996-09-26 1998-04-02 Williams, James, W. Improved therapeutic uses of 4-quinoline-carboxylic acid derivatives

Also Published As

Publication number Publication date
EP1137438A1 (de) 2001-10-04
SK284842B6 (sk) 2005-12-01
ATE218370T1 (de) 2002-06-15
EP1137438B1 (de) 2002-06-05
HK1041598B (zh) 2005-07-15
EA200100647A1 (ru) 2001-12-24
SI1137438T1 (en) 2002-08-31
HUP0104624A2 (hu) 2002-04-29
AR021577A1 (es) 2002-07-24
NZ511882A (en) 2003-11-28
JP2002531525A (ja) 2002-09-24
SK7882001A3 (en) 2001-12-03
EA005136B1 (ru) 2004-12-30
HUP0104624A3 (en) 2002-12-28
AU766810B2 (en) 2003-10-23
PT1137438E (pt) 2002-11-29
HK1041598A1 (en) 2002-07-12
BG105548A (en) 2001-12-29
DE19857009A1 (de) 2000-06-15
BR9916006A (pt) 2001-09-04
MXPA01005861A (es) 2002-03-27
HRP20010429A2 (en) 2002-06-30
PL349336A1 (en) 2002-07-15
ZA200104815B (en) 2002-06-13
ES2178496T3 (es) 2002-12-16
EE200100305A (et) 2002-08-15
CA2354266A1 (en) 2000-06-15
WO2000033876A1 (de) 2000-06-15
YU39901A (sh) 2005-06-10
CN1329506A (zh) 2002-01-02
DK1137438T3 (da) 2002-10-14
DE59901681D1 (de) 2002-07-11
NO20012719L (no) 2001-06-01
NO20012719D0 (no) 2001-06-01
AU1779300A (en) 2000-06-26
IL143586A0 (en) 2002-04-21
KR20010080729A (ko) 2001-08-22
CN1189214C (zh) 2005-02-16

Similar Documents

Publication Publication Date Title
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
PL352547A1 (en) Drugs containing inhibitors of human kinase h-sgk
IL138032A0 (en) Pharmaceutical composition of topiramate
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
EP1062360A4 (en) COMPOUNDS AND METHODS FOR VERTÄARKERRN NUCLEIC ACID MOLECULAR SYNTHASE
HUP9801877A3 (en) Medicaments containing tetrahydrofuryl-sulphonamide-derivative as inhibitors of aspartyl-proteases
HUP0201463A3 (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use
IL118101A0 (en) Inhibitors of farnesyltransferase
IL149592A0 (en) Synthesis of 2'-deoxy-l-nucleosides
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
GB9809869D0 (en) Inhibition of protein kinases
AU4670800A (en) Novel compositions comprising trimetrexate and methods of their synthesis and use
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
IL142539A0 (en) Inhibitors of platelet activation and recruitment
PL343430A1 (en) Preparation and purification of diborane
HUP9702241A3 (en) Use of 2-aminoindan derivatives and pharmaceutical compositions containing them
AU2002213422A1 (en) Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
EP1021407A4 (en) SYNTHESIS OF CLASTO-LACTACYSTINE BETA-LACTONE AND ITS ANALOGS
GB2331926B (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
EP1098659A4 (en) POLYHYDROXAMATE BANKS AND THEIR ANALOG
HUP9802716A3 (en) Pharmaceutical composition of analgesic activity
IL138647A0 (en) Synthesis of compounds and libraries of compounds
HUP0103309A3 (en) Novel salts of n-tert-butylhydroxylamine and preparation thereof
EP1140975A4 (en) STABLE SUBTILIN AND METHOD FOR THE PRODUCTION THEREOF